RM-1 / RM-1-luc Orthotopic Mouse Model Service for Prostate Cancer

The RM-1 / RM-1-luc orthotopic mouse model of prostate cancer places murine prostate tumor cells directly into the prostatic gland of immunocompetent C57BL/6 hosts, recreating the anatomical niche, stromal crosstalk and vascular support that subcutaneous implants cannot provide. From cell line authentication, survival surgery and longitudinal luciferase-based monitoring to necropsy, histopathology and tumor-immune profiling, Alfa Cytology delivers complete, decision-ready RM-1 / RM-1-luc orthotopic programs configured around each sponsor’s mechanism, dosing schedule and endpoint requirements—strictly within a preclinical scope.

Overview of RM-1 / RM-1-luc Orthotopic Mouse Model for Prostate Cancer

RM-1 is a murine prostate carcinoma cell line syngeneic in C57BL/6 mice, first described in the mid-1990s. It was derived from urogenital sinus epithelial cells of a Trp53-deficient C57BL/6 mouse and transformed ex vivo with a recombinant retrovirus (Zipras/myc9) carrying v-Ha-Ras and v-Myc. The cells show a luminal epithelial identity (cytokeratin 18 positive) and express androgen receptor, yet behave aggressively and grow androgen-independently in vivo. Because donor and host share the same genetic background, RM-1 tumors arise in animals with a fully intact immune system—a fundamental advantage over human xenografts propagated in immunodeficient mice.

Fig 1. Longitudinal bioluminescence imaging and survival analysis of orthotopic RM-1-luc prostate tumors treated with TEV scaffold vaccine alone or combined with anti-PD-1. (Chen, Qi, et al., 2026)

In the orthotopic format, RM-1 or RM-1-luc cells are implanted into the prostatic lobe, where the tumor recruits organ-resident stroma, acquires physiological vasculature and develops within an authentic tumor microenvironment. The RM-1-luc derivative constitutively expresses firefly luciferase, permitting non-invasive, serial bioluminescence imaging from the earliest stages of tumor establishment and sensitive detection of occult lesions. These tumors grow remarkably fast—often measurable within days of implantation—and display a characteristically “cold” immune profile with sparse T-cell infiltration and abundant myeloid-derived suppressor cells, so single-agent checkpoint blockade typically yields limited activity while radiotherapy-based combinations can re-sensitize the tumor to immune attack. This biology makes the model a workhorse for preclinical evaluation of immunotherapy combinations, radiation, nanoparticle delivery, androgen-pathway agents and metastatic spread, although its rapid kinetics make it less suitable for long-horizon studies.

Cell Line Information: RM-1 / RM-1-luc

RM-1 and its luciferase-labeled derivative RM-1-luc share the same C57BL/6 genetic background and tumorigenic behavior; the reporter line additionally carries a constitutively expressed firefly luciferase cassette for bioluminescence imaging. Key characteristics are summarized below.

Our Services

Supported by a dedicated in vivo pharmacology team and integrated surgical, imaging and pathology capabilities, Alfa Cytology builds each RM-1 / RM-1-luc orthotopic program around the sponsor’s hypothesis—adjusting inoculum size, randomization, dosing windows and endpoint panels to produce clean, interpretable efficacy data under a strictly preclinical framework.

Workflow of RM-1 / RM-1-luc Orthotopic Mouse Model Construction

Orthotopic construction of the RM-1 / RM-1-luc model is a standardized survival-surgery procedure performed under inhalation anesthesia, with aseptic technique, scheduled analgesia and daily post-operative observation aligned to institutional animal-care standards. A typical engagement proceeds through the following stages:

1. Cell line qualification: RM-1 or RM-1-luc cells are mycoplasma-tested, identity-confirmed, and—for the reporter line—screened for stable, uniform luciferase expression before scale-up.
2. Animal preparation: male C57BL/6 mice (typically 6–8 weeks of age) are acclimatized, health-checked and randomized by body weight prior to surgery.
3. Anesthesia and asepsis: mice are anesthetized with isoflurane, the lower abdomen is disinfected, and sterile instruments and gloves are maintained throughout.
4. Surgical exposure: a small midline abdominal incision is made and the bladder is gently retracted to expose the prostate gland under magnification.
5. Orthotopic inoculation: RM-1 / RM-1-luc cells (commonly 2 × 10⁶ cells in 50 µL of 50% Matrigel) are injected into the dorsal prostatic lobe with a fine-gauge needle to form a confined bleb at the site.
6. Closure and analgesia: the abdominal wall is sutured with absorbable material, the skin is closed with wound clips, and buprenorphine is administered with scheduled follow-up doses until full recovery.
7. Longitudinal monitoring: tumor burden is tracked by serial bioluminescence imaging (D-luciferin, IVIS) for RM-1-luc, supplemented by caliper, ultrasound or CT measurements, together with body weight and clinical scoring.
8. Endpoint and analysis: at termination, tumors are excised and weighed, organs are inspected for metastasis, and tissues are processed for histopathology, immunohistochemistry, flow-cytometric immune profiling and downstream molecular assays.

Fig 2. RM-1 / RM-1-luc orthotopic mouse model construction workflow.

Case Study-RM-1 / RM-1-luc Orthotopic Mouse Model Development

Alfa Cytology maintains an active preclinical case-study library for the RM-1 / RM-1-luc orthotopic platform, spanning longitudinal bioluminescence monitoring of tumor establishment and progression, test-article efficacy and combination immunotherapy regimens, and metastasis assessment with correlated tissue-based readouts. Illustrative datasets—including representative imaging series, growth trajectories and immune-phenotyping summaries—are available upon request and are continually refreshed as new programs reach completion.

Why Choose Alfa Cytology?

Sponsors partner with Alfa Cytology for this model because scientific rigor is engineered into every stage rather than promised at the endpoint:

• A dedicated orthotopic surgery team with a refined, high-survival implantation technique.
• Immediate access to authenticated RM-1 and stably luciferase-labeled RM-1-luc cells.
• Non-invasive bioluminescence tracking that delivers within-animal longitudinal data with reduced variance.
• An immunocompetent C57BL/6 setting suited to immunotherapy, radiotherapy and combination strategies.
• A flexible endpoint menu spanning efficacy, survival, histopathology, IHC, flow cytometry and metastasis staging.
• Study designs tailored to each program’s mechanism of action and decision point.
• Milestone-based communication through a single, responsive project manager.
• A strictly preclinical scope, with every study designed and interpreted as non-clinical research.

Contact Us

To explore how the RM-1 / RM-1-luc orthotopic prostate cancer model can advance your next preclinical program, contact us with your study objectives, timeline and target endpoints. The Alfa Cytology team will respond promptly with a tailored proposal covering model configuration, imaging strategy and endpoint planning—reach out today and let’s move your research forward together.

For research use only. Not intended for any clinical use.